NCT06262919Recruiting
Special Drug Use-results Surveillance of Tafinlar/Mekinist
Observational Study to Assess Safety and Effectiveness of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
This is a prospective, multicenter, single-arm, non-interventional and observational J-PMS conducted by the central registration system and operated in Electronic data capture.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 110 (estimated)
- First submitted
- 8 Feb 2024
- Start date
- 9 Feb 2024
- Primary completion date
- 31 Dec 2031
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Childhood cancers
- NCT number
- NCT06262919
What you commit to
- Study type: Observational
- Planned participants: 110
- From 9 Feb 2024 to the primary completion date, 31 Dec 2031
- 48 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received or are receiving a product containing the same ingredient as the product in any other study or research than this surveillance
Other illness
- Patients with BRAF-mutation-positive malignant melanoma
- Patients with BRAF-mutation-positive non-small cell lung cancer
Other
- Patients with BRAF-mutation-positive hairy cell leukemia
Who the study is looking for
- Patients who have given written consent to cooperate in this surveillance
- For patients aged \< 18 years at the start of treatment with the product, their legally authorized representative must have given written informed consent for cooperation in this surveillance prior to patient enrollment.
- Patients who start treatment with the product for BRAF-mutation-positive advanced/recurrent solid tumors (excluding colorectal cancer) after the approval of additional indications
Age in the registry: 6 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (48)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.